Are Medical Stocks Lagging Alkermes (ALKS) This Year?

Group 1 - Alkermes (ALKS) is currently outperforming its peers in the Medical sector with a year-to-date return of 7.7%, compared to the sector average of 1.7% [4] - The Zacks Rank for Alkermes is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions, with a 15.4% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Alkermes is part of the Medical - Biomedical and Genetics industry, which has seen a year-to-date gain of 10.6%, indicating that ALKS is slightly underperforming its industry [6] Group 2 - The Medical group consists of 956 companies and is currently ranked 4 in the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Another stock in the Medical sector, Brainsway Ltd. Sponsored ADR (BWAY), has significantly outperformed with a year-to-date increase of 68.4% and also holds a Zacks Rank of 2 (Buy) [4][5] - The Medical - Products industry, which includes Brainsway, has a lower ranking at 95 and has gained 5.3% since the beginning of the year [7]